Enalapril

"Enalapril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.

Descriptor ID	D004656
MeSH Number(s)	D12.644.456.345.360
Concept/Terms	Enalapril Enalapril MK-421 MK-421 MK 421 MK421 Renitec Renitec Renitek Enalapril Maleate Enalapril Maleate Maleate, Enalapril

Below are MeSH descriptors whose meaning is more general than "Enalapril".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Oligopeptides [D12.644.456]
Dipeptides [D12.644.456.345]
Enalapril [D12.644.456.345.360]

Below are MeSH descriptors whose meaning is related to "Enalapril".

Below are MeSH descriptors whose meaning is more specific than "Enalapril".

Enalapril
Enalaprilat

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Enalapril" by people in this website by year, and whether "Enalapril" was a major or minor topic of these publications.

Bar chart showing 62 publications over 21 distinct years, with a maximum of 11 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	0	1	1
1993	2	0	2
1995	1	1	2
1996	1	1	2
1998	0	1	1
2001	1	0	1
2004	0	1	1
2007	0	1	1
2009	1	0	1
2010	1	0	1
2011	1	2	3
2013	1	0	1
2014	4	0	4
2015	2	3	5
2016	9	2	11
2017	5	2	7
2018	4	3	7
2019	4	1	5
2020	1	0	1
2021	3	0	3
2022	0	2	2

Below are the most recent publications written about "Enalapril" by people in Profiles.

Wijkman MO, Claggett B, Vaduganathan M, Cunningham JW, Rørth R, Jackson A, Packer M, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shah SJ, Pfeffer MA, McMurray JJV, Solomon SD. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.

View in: PubMed
Mc Causland FR, Lefkowitz MP, Claggett B, Packer M, Senni M, Gori M, Jhund PS, McGrath MM, Rouleau JL, Shi V, Swedberg K, Vaduganathan M, Zannad F, Pfeffer MA, Zile M, McMurray JJV, Solomon SD. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 Sep; 24(9):1591-1598.

View in: PubMed
Bhatt AS, Vaduganathan M, Claggett BL, Liu J, Packer M, Desai AS, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Vardeny O, McMurray JJV, Solomon SD. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.

View in: PubMed
Rohde LE, Claggett BL, Wolsk E, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai AS, Lund LH, Kober L, Anand I, Merkely B, Senni M, Shi V, Rizkala A, Lefkowitz M, McMurray JJV, Solomon SD. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.

View in: PubMed
Ehteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, Petrie MC, Rizkala AR, Rouleau JL, Solomon SD, Swedberg K, Shi VC, Zile MR, Packer M, McMurray JJV, Jhund PS, Hawkins NM. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.

View in: PubMed
Ferreira JP, Mogensen UM, Jhund PS, Desai AS, Rouleau JL, Zile MR, Rossignol P, Zannad F, Packer M, Solomon SD, McMurray JJV. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020 11; 22(11):2056-2064.

View in: PubMed
Goudar SP, Zak V, Atz AM, Altmann K, Colan SD, Falkensammer CB, Friedberg MK, Frommelt M, Hill KD, Hsu DT, Levine JC, Margossian R, Mart CR, Sticka J, Shrader P, Shirali G. Comparison of echocardiographic measurements to invasive measurements of diastolic function in infants with single ventricle physiology: a report from the Pediatric Heart Network Infant Single Ventricle Trial. Cardiol Young. 2019 Oct; 29(10):1248-1256.

View in: PubMed
Selvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund PS, Packer M, Desai AS, Lewis EF, Vaduganathan M, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Solomon SD. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.

View in: PubMed
Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, Rouleau JL, Shi V, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.

View in: PubMed
Zile MR, O'Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M, Rouleau J. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. J Am Coll Cardiol. 2019 02 26; 73(7):795-806.

View in: PubMed

People

Explore

Similar Concepts

Top Journals